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Summary
Apparent defects in cell polarity are often seen in
human cancer [1, 2]. However, the underlying mecha-
nisms of how cell polarity disruption contributes to
tumor progression are unknown. Here, using a Dro-
sophila genetic model for Ras-induced tumor progres-
sion, we show a molecular link between loss of cell
polarity and tumor malignancy. Mutation of different
apicobasal polarity genes activates c-Jun N-terminal
kinase (JNK) signaling and downregulates the E-cad-
herin/b-catenin adhesion complex, both of which are
necessary and sufficient to cause oncogenic RasV12-
inducedbenign tumors in thedeveloping eye to exhibit
metastatic behavior. Furthermore, activated JNK and
Ras signaling cooperate in promoting tumor growth
cell autonomously, as JNKsignaling switches its proa-
poptotic role to a progrowth effect in the presence of
oncogenic Ras. Our finding that such context-depen-
dent alterations promote both tumor growth andmeta-
static behavior suggests that metastasis-promoting
mutationsmay be selected for based primarily on their
growth-promoting capabilities. Similar oncogenic co-
operation mediated through these evolutionarily con-
served signaling pathways could contribute to human
cancer progression.
Results
Most human cancers originate from epithelial tissues.
These epithelial tumors, except for those derived from
squamous epithelial cells, normally exhibit pronounced
apicobasal polarity. However, these tumors commonly
show defects in cell polarity as they progress toward
malignancy [1, 2]. Although the integrity of cell polarity
is essential for normal development [3], how cell polarity
disruption contributes to the signaling mechanisms es-
sential for tumor progression and metastasis is un-
known. To address this, we used a recently established
Drosophila model of Ras-induced tumor progression
triggered by loss of cell polarity. This fly tumor model ex-
hibits many aspects of metastatic behaviors observed in
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ter, Johns Hopkins University School of Medicine, 1650 Orleans
Street, Baltimore, Maryland 21231.human malignant cancers, such as basement mem-
brane degradation, loss of E-cadherin expression, mi-
gration, invasion, and metastatic spread to other organ
sites [4]. In the developing eye tissues of these animals,
loss of apicobasal polarity is induced by disruption of
evolutionarily conserved cell polarity genes such as
scribble (scrib), lethal giant larvae (lgl), or discs large
(dlg), three polarity genes that function together in
a common genetic pathway, as well as other cell polarity
genes such as bazooka, stardust, or cdc42 [3, 5]. Onco-
genic Ras (RasV12), a common alteration in human can-
cers [4, 6], causes noninvasive benign overgrowths in
these eye tissues [4]. Loss of any one of the cell polarity
genes somehow strongly cooperates with the effect of
RasV12 to promote excess tumor growth and metastatic
behavior [4, 7]. However, on their own, clones of scrib
mutant cells are eliminated during development in
a JNK-dependent manner; expression of RasV12 in these
mutant cells prevents this cell death [7].
To better quantify the metastatic behavior of tumors in
different mutant animals, we focused our analysis on in-
vasion of the ventral nerve cord (VNC), a process in
which tumor cells leave the eye-antennal discs and optic
lobes (the areas where they were born) and migrate to
and invade a different organ, the VNC. We further con-
firmed that the genotypes associated with the invasion
of the VNC in this study also resulted in the presence
of secondary tumor foci at distant locations, although
the number and size of these foci were highly variable,
as previously reported [4].
Loss of Cell Polarity Activates JNK Signaling that Is
Essential for Tumor Invasion
In analyzing the global expression profiles of noninva-
sive and invasive tumors induced inDrosophila develop-
ing eye discs, we observed that expression of the JNK
phosphatase puckered (puc) was strongly upregulated
in the invasive tumors (our unpublished data). Upregula-
tion of puc represents activation of the JNK pathway in
Drosophila [8–10]. We therefore utilized an enhancer-
trap allele, puc-LacZ [11], to monitor the activation of
JNK signaling in invasive tumor cells. Strong ectopic
JNK activation was present in invasive tumors (Figures
1D–1F), while only a slight expression of puc was seen
in restricted regions of RasV12-induced noninvasive
overgrowth (Figures 1A–1C). Intriguingly, more intense
JNK activation was seen in tumor cells located in the
marginal region of the eye-antennal disc and tumor cells
invading the VNC (Figures 1D–1I, arrowheads, and also
see Figure S1 in the Supplemental Data available with
this article online). Analysis of clones of cells with a cell
polarity mutation alone revealed that JNK signaling
was activated by mutation of cell polarity genes (Figures
1J–1O). Notably, JNK signaling was not activated in a
strictly cell-autonomous fashion (Figures 1M–1O, arrow-
heads). JNK activation in these cells was further
confirmed by anti-phospho-JNK antibody staining that
detects activated JNK (see Figure S2).
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which Is Triggered by Loss of Cell Polarity
JNK activation was determined by anti-b-ga-
lactosidase staining (magenta) in the genetic
background of puc-LacZ in GFP-labeled
RasV12 benign overgrowth (A–C), RasV12/
dlg2/2 invasive tumors (D–I), or cell polarity-
deficient dlg2/2 clones (J–O) (green). Confo-
cal images of the day 6 cephalic complexes,
which include the eye-antennal discs (EA),
brain hemispheres (BH), the VNC (see also
Figure 2) (A–I), and the day 4 eye discs (J–O)
are shown. JNK is strongly activated in invad-
ing cells in the BH or the VNC ([D]–[I] and
arrowheads. (G)–(I) are high-magnification
images shown by a square in (F). High magni-
fication of dlg2/2 clones shows some non-
cell-autonomous upregulation of puc ([M]–
[O], arrowheads; scale bar, 10 mm). n > 10
for each genotype. See Supplemental Data
for genotypes.To examine the contribution of JNK activation to met-
astatic behavior, we blocked the JNK pathway by over-
expressing a dominant-negative form ofDrosophila JNK
(BskDN). As previously reported [4], clones of cells mu-
tant for scrib, lgl, or dlg do not proliferate as well as
wild-type clones (Figures 2A–2D), while combination of
these mutations with RasV12 expression resulted in mas-
sive and metastatic tumors (Figures 2G, 2G0, 2I, 2I0, 2K,
and 2K0). Strikingly, inhibition of JNK activation by BskDN
completely blocked the invasion of the VNC (Figures
2G0–2L0), as well as secondary tumor foci formation
(see Figure S3). Drosophila has two homologs of TRAF
proteins (DTRAF1 and DTRAF2), which mediate signals
from cell surface receptors to the JNK kinase cascade
in mammalian systems [12]. We found that RNAi-medi-
ated inactivation of DTRAF2, but not DTRAF1, in thetumors strongly suppressed their metastatic behavior
(Figures 2M0 and 2N0). Inactivation of dTAK1, aDrosoph-
ila JNK kinase kinase (JNKKK), or Hep, a JNKK, also
suppressed metastatic behavior (Figures 2O0 and 2P0).
Drosophila has two known cell surface receptors that
act as triggers for the JNK pathway, Wengen (TNF
receptor) and PVR (PDGF/VEGF receptor) [13, 14]. In-
triguingly, we found that RNAi-mediated inactivation of
Wengen partially suppressed tumor invasion (Figure
2Q0). Inactivation of PVR, on the other hand, did not
show any suppressive effect on metastatic behavior
(Figure 2R0). We also found that the metastatic behavior
of RasV12-expressing tumors that were also mutated for
one of three other cell polarity genes, bazooka, stardust,
or cdc42, was also blocked by BskDN (data not shown).
These data indicate that loss of cell polarity contributes
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Dorsal views of the cephalic complexes (A–R) and VNCs (A0–R0) are shown. Wild-type clones do not show any growth advantage (A). Clones with
cell polarity mutation alone result in smaller clones (B–D). RasV12-expressing clones show a moderate growth advantage (E) but never invade the
VNC (E0). Massive tumor growth and invasion to the VNC caused by RasV12/scrib2/2 (G and G0), RasV12/lgl2/2 (I and I0), or RasV12/dlg2/2 (K and K0)
are strongly suppressed by coexpression of BskDN (H, H0, J, J0, L, and L0), RNAi construct of DTRAF2 (N and N0), dTAK1 (O and O0), or Hep (P and
P0), partially suppressed by RNAi of Wengen (Q’, invasion only), but not by RNAi of DTRAF1 or PVR (M, M0, R, and R0). BskDN does not suppress
RasV12-stimulated growth (F). All genotypes displayed 100% phenotypic penetrance (n > 10 for each genotype) except for three genotypes with
RNAi constructs, DTRAF2-IR (N and N0), dTAK1-IR (O and O0), and Wengen-IR (Q0), which still showed 89% (n = 19), 63% (n = 41), and 48% (n = 31)
penetrance, respectively. See Supplemental Data for genotypes.
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conserved JNK pathway.
Activation of JNK and Inactivation of E-Cadherin/
b-Catenin Are Downstream Events of Cell Polarity
Disruption that Trigger Tumor Invasion
We next examined whether JNK activation is sufficient
to trigger metastatic behavior in RasV12-induced benign
tumors. Two genetic alterations can be used to activate
JNK in Drosophila. First, JNK signaling can be activated
by overexpression of Eiger, a Drosophila TNF ligand [15,
16]. While mammalian TNF superfamily proteins activate
both the JNK and NFkB pathways, Eiger has been
shown to specifically activate the JNK pathway through
dTAK1 and Hep [15]. Indeed, the eye phenotype caused
by Eiger overexpression could be reversed by blocking
JNK through Bsk-IR (Bsk-RNAi) (Figures 3N and 3O).
Second, overexpression of a constitutively activated
form of Hep (HepCA) can also activate JNK signaling
[8]. However, the eye phenotype caused by HepCA over-
expression was only slightly suppressed by Bsk-IR (Fig-
ures 3P and 3Q), suggesting that HepCA overexpression
may have additional effects other than JNK activation.
We therefore used Eiger overexpression to activate
JNK in RasV12-induced benign tumors and found that
the RasV12+Eiger-expressing tumor cells did not result
in the invasion of the VNC (Figure 4P and data not
shown). This indicates that loss of cell polarity must in-
duce an additional downstream effect(s) essential for
metastatic behavior. A strong candidate for the missing
event is downregulation of the E-cadherin/catenin adhe-
sion complex, since this complex is frequently downre-
gulated in malignant human cancer cells [17, 18] and is
also downregulated by loss of cell polarity genes in
Drosophila invasive tumors [4] (and data not shown). In
addition, it has been recently reported that higher motil-
ity of mammalian scrib knockdown cells can be partially
rescued by overexpression of E-cadherin-catenin fusion
protein [19], suggesting a role of E-cadherin in prevent-
ing polarity-dependent invasion. Furthermore, over-
expression of E-cadherin blocks metastatic behavior
of RasV12/scrib2/2 tumors [4], indicating that loss of E-
cadherin is essential for inducing tumor invasion in this
model. We found that loss of the Drosophila E-cadherin
homolog shotgun (shg), combined with the expression
of both RasV12 and Eiger, induced the invasion of the
VNC (88% penetrance, n = 119) (Figure 3D0, arrow-
heads). Intriguingly, loss of shg in RasV12-expressing
clones also showed a weak invasive phenotype at lower
penetrance (20%, n = 101) (Figure 3B0, arrowheads). In
agreement with the essential role of JNK in tumor
invasion, clones of shg2/2 cells weakly upregulated
puc expression (Figures 3G–3I). We further found that
JNK activation in dlg2/2 clones was not blocked by
overexpression of E-cadherin (Figures 3J–3L), suggest-
ing that mechanism(s) other than loss of E-cadherin
also exist for inducing JNK activation downstream of
cell polarity disruption. The metastatic behavior of
RasV12+Eiger/shg2/2 tumors was completely blocked
by coexpression of BskDN (Figure 3E0), indicating
a cell-autonomous requirement of JNK activation for
this process. Furthermore, we found that loss of the b-
catenin homolog armadillo also induced metastatic be-
havior in RasV12-induced benign tumors (see Figure S4).On the other hand, overexpression of HepCA in RasV12/
shg2/2 cells resulted in neither enhanced tumor growth
nor metastatic behavior (Figures 3F and 3F0), which is
consistent with our data (Figures 3N–3Q) and the previ-
ous report [20]. Together, these results suggest that,
although the RasV12+Eiger/shg2/2 does not completely
phenocopy the effect of RasV12/scrib2/2, activation of
JNK signaling and inactivation of the E-cadherin/catenin
complex are the downstream components of cell polar-
ity disruption that trigger metastatic behavior in RasV12-
induced benign tumors.
JNK Activation Is Essential for Accelerated Tumor
Growth
Aside from its evolutionarily conserved role in cell migra-
tion and invasion [10, 21], JNK signaling is also a potent
activator of cell death inDrosophila and mammals [8, 15,
22]. Although RasV12-expressing tissues showed a weak
and restricted activation of JNK at later stages of devel-
opment, mutation of cell polarity genes in combination
with RasV12 expression constitutively activated JNK sig-
naling (see Figure S5). Striking acceleration of tumor
growth occurred during days 5 and 6, and these tumors
outcompeted surrounding wild-type tissues, resulting in
a loss of the unlabeled wild-type cells and a dramatic in-
crease in the GFP-expressing mutant tissue (see
Figure S5). The activated JNK was correlated with this
accelerated tumor growth, suggesting that JNK signal-
ing may play a role in tumor growth (see Figure S5).
Indeed, in addition to blocking metastatic behavior, inac-
tivation of JNK pathway components strongly sup-
pressed the accelerated tumor growth caused by cell
polarity disruption (Figures 2G–2P). These results reveal
that JNK signaling activated by loss of cell polarity also
stimulates tumor growth.
Tumor Growth and Invasion Are Separable
Processes
Since JNK signaling was required for both tumor growth
and invasion, we next asked whether these two pheno-
types were separable processes. To address this, we
analyzed different types of tumors caused by alterations
in genes involved in cell proliferation, growth, and cell
polarity. Day 6 RasV12/scrib2/2 tumors showed moder-
ate tumor growth and VNC invasion phenotypes (Fig-
ures 4A and 4A0). Loss of the Akt gene, a component
of insulin growth signaling, considerably reduced the
tumor load of RasV12/scrib2/2 animals but did not impair
metastatic behavior (Figures 4B and 4B0). On the other
hand, overexpression of Akt, combined with mutations
in both the scrib gene and the lats gene, a potent tumor
suppressor [23], did not cause metastatic behavior de-
spite accelerated tumor growth comparable to RasV12/
scrib2/2 (Figures 4C and 4C0). In addition, although
RasV12/Tsc12/2 mutant cells resulted in extremely large
tumors, these tumor cells never exhibited metastatic
behavior (Figure 4D). These data indicate that tumor
growth and invasion are separable processes in this
model system.
JNK Switches Its Proapoptotic Role to a Progrowth
Effect in the Presence of Oncogenic Ras
Consistent with previous reports [7, 20], we found that
JNK signaling was indeed activated in polarity-deficient
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1143Figure 3. Activation of JNK Signaling and In-
activation of E-Cadherin Are Downstream El-
ements of Cell Polarity Disruption that Trigger
Metastatic Behavior and Accelerated Growth
in RasV12-Induced Tumors
(A–F and A0–F0) Cephalic complexes (A–F)
and brain-VNCs (A0–F0) with GFP-labeled
(green) clones of RasV12 (A and A0), RasV12/
shg2/2 (day 12) (B and B0), Eiger/shg2/2 (C
and C0), RasV12+Eiger/shg2/2 (day 12) (D
and D0), RasV12+Eiger+BskDN/shg2/2 (E and
E0), and RasV12+HepCA/shg2/2 (F and F0) are
shown. The penetrance of VNC invasion phe-
notype for each genotype is also shown.
(G–L) Confocal images of anti-b-galactosi-
dase staining (magenta) of the eye discs
with clones (green) of shg2/2 (G–I) or E-cad-
herin/dlg2/2 (J–L) in the genetic background
of puc-LacZ is shown.
(M–Q) Wild-type eye (M) and eyes overex-
pressing Eiger (N and O) or HepCA (P and Q)
without (N or P) or with (O or Q) RNAi con-
struct of Bsk (Bsk-IR) are shown. All flies
were raised at 25ºC, except that GMR>HepCA
flies (P) were raised at 18ºC because of their
pupal lethality at 25ºC. See Supplemental
Data for genotypes.cells (Figures 1J–1O), and acridine orange staining re-
vealed that most of these cells were dying (Figures 4E–
4G). Interestingly, ectopic cell death was mostly blocked
within clones of polarity-deficient cells also expressingRasV12 (Figures 4H–4J) [7], despite strong JNK activation
(Figures 4K–4M). In addition, coexpression of RasV12 and
Eiger, a potent inducer of cell death [15, 16] (Figure 3N),
resulted in accelerated tumor growth (Figure 4P),
Current Biology
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(A–D) Tumor growth and invasion are separable processes. Dorsal views of the cephalic complexes (A–D) and VNCs (A0-C0) with different types of
tumors are shown. Invasion of the VNC can be seen without significant tissue overgrowth (B and B0), while accelerated growth is not sufficient to
cause VNC invasion (C, C0, and D0). n > 10 for each genotype.
(E–Q) JNK signaling switches its proapoptotic role to a progrowth effect in the context of Ras activation. Dying cells were visualized by acridine
orange staining (green) in day 4 eye discs with dlg2/2 (E–G) or RasV12/dlg2/2 (H–J) clones (magenta). Red fluorescent protein (RFP) was used for
labeling clones to distinguish them from the green staining of acridine orange. JNK activation was detected by anti-b-galactosidase staining
(magenta) within RasV12/dlg2/2 clones (green) in day 4 eye discs (K–M). More than 50 clones are analyzed in each experiment in E-M. (N–Q) Ce-
phalic complexes with GFP-labeled clones of RasV12 (N), Eiger (O), RasV12+Eiger (P), and RasV12+Eiger+BskDN (Q) are shown. At days 10–14,
combined expression of RasV12 and Eiger using a weak or a strong allele of UAS-Eiger resulted in massive tumor growth (P) with 24.1% (n =
245) or 44.1% (n = 229) penetrance, respectively. n > 10 for each genotype. See Supplemental Data for genotypes.
(R) A model for polarity disruption-induced oncogenic cooperation among the Ras, JNK, and E-cadherin pathways that causes tumor growth and
invasion. Clones of cells expressing RasV12 alone cause noninvasive benign overgrowth (Ra). Clones of cells with disrupted cell polarity alone
result in JNK activation and subsequent cell death (Rb). Loss of cell polarity in the presence of oncogenic Ras results in accelerated tumor growth
and invasion through cooperation of Ras and JNK activation and E-cadherin (E-cad) inactivation (Rc). The proapoptotic effect of JNK signaling
(Rb) is converted to a progrowth effect in the presence of oncogenic Ras (Rc).although neither RasV12 alone nor Eiger alone caused
dramatic overgrowth (Figures 4N and 4O). This massive
overgrowth was completely blocked by coexpression
of BskDN (Figure 4Q). Moreover, stimulation of JNK sig-
naling by expressing Eiger dramatically enhanced tumor
growth of RasV12/shg2/2 tissues (compare Figures 3B
and 3D), although Eiger/shg2/2 clones were very small(Figures 3C), probably because of cell death of these mu-
tant clones. The accelerated growth of the RasV12+Eiger/
shg2/2 tumors was again completely blocked by BskDN
(Figure 3E). Together, these data indicate that, in the con-
text of oncogenic Ras, JNK activation is the primary me-
diator of tumor growth downstream of cell polarity dis-
ruption. Our observations suggest that JNK signaling
Polarity Loss-Triggered Tumor Malignancy
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presence of oncogenic Ras, and that the dramatic tumor
growth is caused by cooperation between oncogenic
Ras and JNK signaling.
Discussion
Our study provides a molecular link between loss of cell
polarity and tumor malignancy, namely activation of JNK
signaling and inactivation of the E-cadherin/catenin
complex in the context of oncogenic Ras activation. Al-
though RasV12 alone only induces noninvasive over-
growth, and loss of cell polarity alone results in JNK-me-
diated cell death, the combination of these two
alterations promotes both tumor growth and invasion
through oncogenic cooperation (Figure 4R). Thus, the
tumor-promoting alterations caused by loss of cell po-
larity do not function alone and rather act as oncogenic
Ras modifiers or ‘‘oncomodifiers.’’
The JNK signaling is essential for a variety of biologi-
cal processes such as morphogenesis, cell proliferation,
migration, invasion, and cell death [22]. Genetic studies
in Drosophila have demonstrated that JNK signaling is
essential for epithelial cell movements and invasive be-
havior during normal development [10, 21, 22]. A genetic
study in mice revealed that TNF-triggered JNK signaling
stimulates epidermal proliferation [24]. These studies
suggest that JNK may play an important role in tumori-
genesis, tumor growth, and metastasis. Indeed, a sub-
stantial body of evidence indicates that JNK activation
and c-Jun phosphorylation play important roles in can-
cer development (e.g., reviewed in [25]). In mammalian
cell culture systems, Ras acts cooperatively with JNK
or c-Jun to enhance cellular transformation [26–28]. Fur-
thermore, knockin mice expressing a mutant form of c-
Jun (JunS63A,S73A) suppress development of skin tumors
in response to Ras activation [29] and also block devel-
opment of intestinal epithelial cancers caused by APC
mutation [30]. Moreover, liver-specific inactivation of
c-Jun impairs development of chemically induced hepa-
tocellular carcinomas [31]. Furthermore, JNK signaling
is activated in many tumor types (e.g., reviewed in
[32]). On the contrary, however, it has been also shown
that JNK functions as a negative regulator for tumor de-
velopment in Ras/p53-transformed fibroblasts [33].
Thus, the role of JNK signaling seems to be highly de-
pendent on cellular context, and, to our knowledge,
our study provides the first evidence for a cell-autono-
mous oncogenic cooperation between JNK and Ras sig-
naling that promotes tumor growth and malignancy.
How is JNK signaling activated? Loss of cell polarity
may directly influence activity of a JNK pathway compo-
nent. Alternatively, cell polarity defects may activate
a cell surface receptor that triggers JNK signaling. Our
genetic analysis of multiple JNK pathway components
suggests that the pathway is activated through a cell
surface receptor, Wengen. It would be interesting to fur-
ther investigate whether mislocalization or disregulation
of Wengen, which should be normally tightly regulated in
polarized epithelial cells, results in stimulation of JNK
pathway signaling.
Our discovery that metastasis-promoting alterations
(i.e., JNK activation) also increase tumor growth may ex-
plain why tumor cells acquire such mutations; that is,they primarily provide a selective advantage in tumor
growth. Given that cell polarity defects are frequently as-
sociated with human tumor malignancy, and that the
pathways identified inDrosophila are evolutionarily con-
served, similar molecular mechanisms could be in-
volved in human tumor progression. It would be partic-
ularly interesting to study these processes in human
tumors with high frequencies of Ras mutations. If such
processes prove conserved, components of these path-
ways, especially JNK signaling, could serve as potential
therapeutic targets against such cancers.
Experimental Procedures
Fly Strains and Generation of Clones
Fluorescently-labeled noninvasive or invasive tumors were pro-
duced in the eye discs as previously described [4] using the follow-
ing strains: Tub-Gal80, FRT19A; eyFLP5, Act>y+>Gal4, UAS-GFP
(19A tester), y,w, eyFLP1; Tub-Gal80, FRT40A; Act>y+>Gal4, UAS-
GFP (40A tester), y,w, eyFLP1; FRT43D, Tub-Gal80; Act>y+>Gal4,
UAS-GFP (43D tester), y,w, eyFLP1; Act>y+>Gal4, UAS-GFP;
FRT82B, Tub-Gal80 (82B tester), and y,w, eyFLP1; Act>y+>Gal4,
UAS-myrRFP, G454; FRT82B, Tub-Gal80 (82B RFP tester). Addi-
tional strains used in this study are described in Supplemental
Data. UAS-DTRAF1-IR, UAS-DTRAF2-IR, and a weak allele of
UAS-Eiger (UAS-eigerW) were kind gifts of M. Miura. UAS-myrRFP
was a kind gift of H. Chang.
Histology
Larval tissues were stained using standard procedures for confocal
microscopy. A rabbit anti-b-galactosidase antibody (Cappel, 1:200)
and Cy3-conjugated secondary antibody (Jackson Labs) were used.
For the analysis of metastatic behavior, the pattern of GFP-express-
ing mutant cells was carefully observed in the eye discs, brain hemi-
spheres, VNC, and other larval tissues using a Leica MZ FLIII fluores-
cence stereomicroscope, a BioRad 1240 confocal microscope, and
a Zeiss LSM510 META confocal microscope. See also Supplemental
Data for additional experimental procedures for histology.
Supplemental Data
Supplemental Data include five figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with
this article online at http://www.current-biology.com/cgi/content/
full/16/11/1139/DC1/.
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